In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genocea Biosciences closes $35mm Series B

Executive Summary

Vaccines developer Genocea Biosciences Inc. has raised $35mm in its Series B financing round. First-time backers Johnson & Johnson Development Corp., Skyline Ventures (adds a board member), and MP Healthcare Venture Management were joined by returning shareholders Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners, and Morningside Ventures. Funds will support ongoing pipeline development, including the initiation of clinical trials for Genocea's lead vaccine candidate for herpes simplex virus Type 2. The company's early-2009 Series A brought in $23mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies